title: [Efficacy of stereotactic radiotherapy for primary and metastatic liver cancer].
abstract: Twenty patients( 30 nodules) with metastatic liver cancer( MLC) and 10 cases with hepatocellular carcinoma( HCC) treated by stereotactic radiotherapy (SRT) were analyzed. SRT was administered at 48.0 or 52.8 Gy/4 Fr/1 wk. The response rate (RR) in MLC patients was 78%, and 11 patients survived longer than 1 year and 9 patients survived as long as 2 years. Clinical analysis suggests that the ideal indications for SRT in MLC are solitary nodules in patients without extrahepatic disease who have undergone systemic chemotherapy. Although RR of SRT for HCC was as high as 85%, intrahepatic recurrence was observed in all patients and 6 patients died within 1 year. Further analysis is needed to determine the indication for SRT in HCC patients.
authors.affiliation: Dept. of Surgery, NTT West Osaka Hospital.
authors.forename: Takeshi
authors.initials: T
authors.lastname: Tono
authors.forename: Kazuhiko
authors.initials: K
authors.lastname: Hashimoto
authors.forename: Yuji
authors.initials: Y
authors.lastname: Yamada
authors.forename: Kentaro
authors.initials: K
authors.lastname: Nishida
authors.forename: Takahiro
authors.initials: T
authors.lastname: Yanagawa
authors.forename: Katsuki
authors.initials: K
authors.lastname: Danno
authors.forename: Yujiro
authors.initials: Y
authors.lastname: Fujie
authors.forename: Shoichiro
authors.initials: S
authors.lastname: Fujita
authors.forename: Junya
authors.initials: J
authors.lastname: Fujita
authors.forename: Tetsuya
authors.initials: T
authors.lastname: Yoshida
authors.forename: Tadashi
authors.initials: T
authors.lastname: Onishi
authors.forename: Shingi
authors.initials: S
authors.lastname: Imaoka
authors.forename: Takushi
authors.initials: T
authors.lastname: Monden
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D000970:Antineoplastic Agents / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy / Q000473:pathology / Q000532:radiotherapy* / Q000556:secondary; D008297:Male; D008875:Middle Aged; D011379:Prognosis
chemical_list: D000970:Antineoplastic Agents